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Abstract
Recent studies identifying putative truncated androgen receptor isoforms with ligand-independent activity have shed new
light on the acquisition of androgen depletion independent (ADI) growth of prostate cancer. In this study, we present a
model system in which a C-terminally truncated variant of androgen receptor (TC-AR) is inducibly expressed in LNCaP, an
androgen-dependent cell line, which expresses little truncated receptor. We observed that when TC-AR is overexpressed,
the endogenous full length receptor (FL-AR) is transcriptionally downmodulated. This in essence allows us to ‘‘replace’’ FL-
AR with TC-AR and compare their individual properties in exactly the same genetic and cellular background, which has not
been performed before. We show that the TC-AR translocates to the nucleus, activates transcription of AR target genes in
the absence of DHT and is sufficient to confer ADI growth to the normally androgen dependent LNCaP line. We also show
that while there is significant overlap in the genes regulated by FL- and TC-AR there are also differences in the respective
suites of target genes with each AR form regulating genes that the other does not. Among the genes uniquely activated by
TC-AR is RHOB which is shown to be involved in the increased migration and morphological changes observed in LN/TC-AR,
suggesting a role of RHOB in the regulation of androgen-independent behavior of prostate cancer cells.
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Introduction
Prostate cancer (CaP) initially presents as an androgen
dependent (AD) disease, but frequently progresses to an androgen
depletion independent (ADI) or castration-resistant state. As the
latter escapes therapies which target the androgen receptor
signaling axis, considerable efforts have been made to more
thoroughly understand both the transition to and biology of ADI
disease. The most representative in vitro model of CaP transition
from AD to ADI growth is the CWR22Rv1 cell line. Like the AD
CaP cell line LNCaP, CWR22Rv1 retains a functional androgen
receptor (AR) and, as such, is responsive to the presence or
absence of DHT. However, in contrast to LNCaP and more in
line with advanced CaP cell lines, CWR22Rv1 is not dependent
upon the presence of DHT for growth.
Because of the unique niche it occupies within the collection of
CaP cell lines, CWR22Rv1 has been studied extensively within the
context of acquisition of ADI growth. As expected, considerable
research has focused on the CWR22Rv1 androgen receptor (AR)
which has been shown to carry the common H874Y mutation [1]
as well as a duplication of exon 3 [2,3]. We previously reported
that CWR22Rv1 and the relapsed CWR22 variant xenograft from
which it was derived express an AR with a duplication of exon 3,
which is accompanied by a high level of truncated AR. These
properties are not present in the original androgen-dependent
CWR22 xenograft, and we suggested that the truncated receptor
may be responsible for the transition to its androgen-independent
state. Using antibodies targeting different regions of AR, we
mapped the truncated receptor species to be the N-terminal half of
the molecule, consisting of NTD and DBD [2]. Since that initial
characterization, the genome of CWR22Rv1 has been found to
carry an intragenically duplicated AR locus [4], which may
account at least in part for the generation of full-length AR (FL-
AR) with a duplicated exon 3 and the wide range of splice variants,
although the exact mechanisms remain to be elucidated.
Studies by Libertini et al [5] implicated calpain in the
proteolytic cleavage of full length receptor, contributing to some
of the truncated receptors. By contrast, the work of Dehm et al [6]
suggested AR spliced variants (AR1/2/2b and AR1/2/3/2b) are
largely responsible for the generation of the truncated receptors in
CWR22Rv1. Work by Hu et al [7] and Guo et al [8], identified
several additional spliced variants and found that AR3/AR-V7,
but not AR1/2/2b or AR1/2/3/2b is the predominant species in
CWR22Rv1. Guo et al, went on to develop antibodies against
AR3 and conclusively identified the presence of the truncated
receptor corresponding to AR3. While the direct demonstration of
a cleaved product at the protein level is more challenging than the
detection of spliced transcripts, none of the studies have excluded
the contributions of truncated receptor generated by proteolytic
cleavage. Indeed, Hornberg et al [9] showed that there is a
disparity between the amount of truncated receptor and the level
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of spliced variants. We therefore favor the hypothesis that
truncated receptors can be generated through both proteolytic
cleavage and alternative splicing.
The schematic structure of the prototypic AR truncated variants
in our reports as well as in other studies is shown in Figure 1A.
Based on the protease cleavage model, the truncated AR would
have a duplicated exon 3 and a C-terminal putative calpain
cleavage site in the hinge region (Figure 1A (i)). The most
abundant and well characterized splice variant is AR3/AR-V7
which has a similar structure except the last 16 C-terminal amino
acids are derived from a cryptic exon (CE3) [7,8,10]. Another
recent study also found a novel human AR splice variant
(ARv567es) from prostate cancer xenografts with exons 5, 6, and
7 deleted, which is constitutively active in prostate cancer cell lines
[11]. There are other splice variants similar to these prototypes,
which are present less abundantly in prostate cancer cell line or
tissues, and of which the protein products have yet to be identified
[10,12,13]. These variants all lack the major part of the ligand
binding domain and their activities are ligand-independent.
Although in FL-AR the hinge domain is required for nuclear
localization [14], most reported splice variants are lacking the
hinge region (and the nuclear localization signal encoded within
it). However, as in the case of AR3/AR-V7, this deletion may be
compensated for by a cryptic exon rich in lysine residues [12].
Most of the previous studies on truncated receptors have
focused on their ability to transactivate androgen-responsive genes
and to induce androgen-independent growth [6–8]. These studies
were carried out primarily either in androgen-insensitive, AR
negative cells, or in androgen-responsive cells with a high level of
FL-AR, which preclude the analysis of isolated TC-AR in its
natural androgen-responsive background. The presence of FL-AR
apparently can affect the function of the spliced variants in a cell
context dependent manner [10,15]. Furthermore, most of the
biological studies utilize clones derived from transduction or
transfection of cDNA carrying truncated receptors, which may
have acquired properties different from the parental cells. As a
potentially more attractive model, we present here the establish-
ment of LN/TC-AR, a novel cell line derived from the androgen
dependent LNCaP parental line in which expression of a C-
terminally truncated AR (TC-AR) is regulated and titratable by
doxycycline and automatically down modulates the expression of
the endogenous FL-AR. As such, when uninduced, the main AR
species is the FL-AR of LNCaP, whereas upon induction, TC-AR
of CWR22Rv1 predominates. The biological and transactivational
properties of FL-AR and TC-AR can thus be studied in exactly the
same genetic and cell background.
To demonstrate the utilization of this cell line, we report the
presence of autoregulation of AR expression levels, acquisition of
ADI growth, and changes in cell shape and migration following
induction of TC-AR. We also extend upon reporter assays
involving C-terminally truncated AR forms to show occupancy at
an AR regulated promoter and transcriptional activation of an AR
regulated gene. Using microarray and qRT-PCR, we report on
the common and unique genes regulated by TC-AR and DHT-
bound endogenous AR. Lastly, while its effect is not directly
involved in ADI growth, we identify RHOB, a gene we show to be
upregulated by TC-AR, but not by DHT-bound endogenous FL-
AR, to be a possible effector of morphological and migration
differences during the transition to ADI disease. As the AR forms
in these cell lines represent the minimal common domains shared
by all functional ligand-independent AR, the data generated by
this study will likely be applicable to similarly truncated receptors.
Materials and Methods
Plasmid Construction
TC-AR was PCR amplified (forward primer: 59-ggatccaatg-
taagtgcagttagggctggg-39; reverse primer: 59-ctcgagtcatagtttcagat-
taccaagtttcttcagcttcc-39) from cDNA derived from CWR22Rv1,
TOPO cloned and verified for sequence accuracy. The insert was
then excised from the cloning vector using BamHI and XhoI
restriction sites and ligated into a similarly digested modified form
of pLenti4/TO/V5-DEST (Invitrogen). Subcloning was done
such that TC-AR was placed immediately downstream and in
frame with sequence encoding the FLAG epitope to produce the
lentiviral expression plasmid pLenti4/TO/FLAG-TC-AR.
Cell Lines
LNCaP and 293T cells were obtained from ATCC and cultured
in RPMI or DMEM, respectively, both of which were supple-
mented with 10% FBS and 1% PSG. All cells were cultured at
37C in the presence of 5% CO2 in air. Stable cell lines derived
from the parental LNCaP line were each established following
lentiviral transduction and drug selection of stable transductants
using the ViraPower tRex system (Invitrogen) according to
manufacturer’s instructions. Briefly, 293T cells were co-transfected
with each of three helper plasmids along with the appropriate
expression or knockdown plasmid. Lentiviral particle-containing
supernatant was then harvested 48-hours post transfection, filtered
and applied to the appropriate parental cells which were then
cultured in the presence of blasticidin (10 ng/mL; Invitrogen),
zeocin (100 ng/mL; Invitrogen) or puromycin (0.5 ug/mL;
Invitrogen). Drug resistant clonal populations were then isolated,
expanded and analyzed for gene expression or gene knockdown by
western blot. A summary of cell lines reported here and their
derivation (parental line; expression plasmid; drug selection) is as
follows: LNCaP/TR (LNCaP; pLenti6/TR; blasticidin), LN/TC-
AR (LNCaP/TR; pLenti4/TO/FLAG-TC-AR; zeocin) and LN/
TC-AR/shR-RHOB (LN/TC-AR; pLKO.1/shR-RHOB; puro-
mycin). Lentiviral plasmids encoding shRNA sequence targeting
RHOB were purchased from Open Biosystems. Plasmid name with
corresponding mature anti-sense region is pLKO.1/shRHOB;
AACTCGTCCTTACTGAACACG.
Western Blot Analysis
Cells were lysed in RIPA buffer supplemented with Complete
Protease Inhibitor Cocktail (Roche). Nuclei and cellular debris
were removed by centrifugation at 14,0006g for 15 min. at 4 C.
Protein concentration was then assayed using the BCA Protein
Assay Reagent (Pierce). 100 mg samples were then separated by
denaturing SDS-PAGE and transferred to PVDF membranes
(Immobilon). Membranes were blocked for 90 min. in 5% NFDM
in TBST. Primary antibodies a-FLAG M2 (Sigma-Aldrich), a-AR
(PG-21) (Millipore), a-actin (Sigma-Aldrich) and a-RHOB (Santa
Cruz) were diluted in 5% NFDM in TBST according to
manufacturer’s recommendations and incubated with the mem-
branes overnight at 4 C. Membranes were then washed twice with
TBST for 15 min. and incubated with either a-mouse or a-rabbit
secondary antibody conjugated to HRP (Santa Cruz) and diluted
1:5000 in 5% NFDM in TBST for 90 min. at RT. Membranes
were washed twice with TBST and developed with Supersignal
(Pierce) and exposed to Bio-Max X-Ray film (Kodak).
Co-immunoprecipitation Assay
LN/TC-AR cells were grown in RPMI 1640 supplemented
with 10% FBS/1% PSG and induced with 4 ng/mL doxyxycline
for a period of 48 hours with uninduced cells serving as a negative
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control. Cells were lysed in Pierce’s IP lysis buffer supplemented
with Halts protease and phosphatase inhibitors (Pierce Biotech-
nology) and samples were centrifuged (15 krpm; 10 m; 4 C) to
clear lysate. Supernatant was then transferred to a fresh 1.5 mL
centrifuge tube and concentration was determined by BCA assay.
An aliquot of cell lysate was reserved as an input control and
500 mg lysate was mixed with 50 uL of a 50% slurry of a-FLAG
M2 agarose beads (Sigma Aldrich) and incubated overnight at 4 C
with constant rotation. Beads were washed 36with 1 mL Pierce’s
IP buffer and eluted with 30 mL 66 sample buffer. Samples were
resolved on a 6% polyacrylamide gel and transferred to a PVDF
membrane. Membranes were probed with a-AR(PG-21) followed
Figure 1. Expression of FLAG-tagged TC-AR in LN/TC-AR cell line suppresses endogenous AR at both transcriptional and
translational levels. A Schematic structure of prototypic AR truncated variants. (i) Two truncated AR variants used in our study. (ii) AR splice
variants from Guo et al 2009 and Hu et al 2009. (iii) AR splice variants from Dehm et al 2008. (iv) AR splice variant from Sun et al 2010. Numbers
represent exon numbers. 2b, 3b, CE1, and CE3 represent cryptic exons. The length of translated sequence by cryptic exons is shown at the right. B
Membrane was probed with a-FLAG M2. Right lane contains 100 mg whole cell lysate harvested from LN/TC-AR cells induced with 100 ng/mL
doxycycline for 48 hours. Left lane contains 100 mg whole cell lysate harvested from uninduced LN/TC-AR. C LNCaP (LN) and CWR22Rv1 (CWR) lysates
serve as control for LN/TC-AR cells which were treated with various concentrations of doxycycline. All lanes contain 100 mg whole cell lysate per lane
and the membrane was probed with a-AR(PG-21). D LN/TC-AR cells were treated with either Low Dox or High Dox. At designated time points, RNA
was isolated and quantitative RT-PCR was performed to determine mRNA levels of endogenous AR and TC-AR. Fold induction is relative to uninduced
LN/TC-AR control. E Co-immunoprecipitation assay reveals that in LN/TC-AR cells induced with 4 ng/mL doxycycline (Lanes 3&4), TC-AR, but not FL-
AR, is precipitated by IP with a-FLAG agarose beads (Lanes 4) indicating that the two AR forms do not heterodimerize. As controls, identically
prepared/immunoprecipitated uninduced LN/TC-AR cell lysate is shown in Lanes 1 (WCL) and 2 (IP).
doi:10.1371/journal.pone.0049887.g001
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by HRP-conjugated a-Rabbit developed with SuperSignal and
imaged on a Cell Biosciences western blot imager.
Luciferase Assay
LN/TC-AR cells were seeded to 24-well plates at a density of
60 K/well and incubated overnight at 37 C. The following day,
cells were co-transfected with pPSA6.0-luc (180 ng/well) and
pH 48-ren (20 ng/well) using Effectene Transfection Reagent
(Qiagen) and treated with either DHT or various concentrations of
doxycycline. Forty-eight hours post-transfection/treatment, cells
were lysed and assayed for luciferase and renella production using
the Dual-luciferase Assay Kit (Promega) as recommended by the
manufacturer on an EG&G Berthold LB96V MicroLumatPlus
microplate luminometer (Perkin-Elmer-Wallace, Inc.). All sample
groups were completed in triplicate (mean values are reported) and
have been normalized for transfection efficiency using the renella
relative light units (RLU) acquired for each sample.
Immunostaining
LN/TC-AR cells were plated to 6-well plates with one slide in
each well and were hormone-depleted for 3 days then treated with
4.5 ng/mL doxycycline treatment or vehicle only as control for
24 hours. Slides were washed with 16PBS twice and fixed in 4%
paraformaldehyde at 4uC for 30 minutes. After three washes with
16 PBS, slides were permeabilized with 1% Triton X-100 in 16
PBS followed by 1% NP-40 in 16PBS for 10 minutes. Slides were
blocked with 2% BSA in TBST for 30 minutes then washed 3
times with 16PBS. Anti-FLAG M2 antibody was diluted 1:50 in
2% BSA in TBST and incubated with slides for one hour at room
temperature (RT). Slides were then washed with 16PBS 3 times
and incubated with Alexa Fluor 488 goat-a-mouse secondary
antibody (Invitrogen) at RT for one hour. Slides were washed 3
times with 16 PBS and mounted with SlowFade and DAPI
(Invitrogen). Images were acquired with an Olympus fluorescent
microscope using appropriate filter sets.
Cell Growth Assays (Cell Counts & MTT)
Cell count assay. Cells were plated to 6-well plates at a
density of 26105 cells/well in RPMI1640 supplemented with
10%CDT-FBS, 1%PSG. After 24 hours, cells were treated with
DHT 1 nM, Dox 4.5 ng/mL, Dox 20 ng/mL and vehicle only as
control. Medium was refreshed every 72 hours. Individual
treatments were in duplicate. At the reported time points, cells
were washed gently with PBS and trypsinized 2–3 minutes at RT.
Total cells per well were determined via CountessH Automated
Cell Counter (Invitrogen) according to the manufacturer’s
protocol.
MTT assay. Cells were plated to 24-well plates at a density of
20 K cells/well in RPMI1640 supplemented with 10%CDT-FBS,
1%PSG. After 24 hours, cells were treated with DHT 1 nM, Dox
4.5 ng/mL, Dox 20 ng/mL and vehicle only as control. At the
designated time points, 30 mL MTT labeling reagent was added to
each well and incubated 4 hours at RT. Following the four hour
incubation, 300 mL of the Solubilization Solution was added to
each well and the plates were incubated overnight. The following
day, absorbance of the formazan product was measured at A570
on a microplate reader.
Cell Migration Assays
Cell migration assay kit (ECM 509) was purchased from
Millipore (CHEMICON) and the commercial protocol from
Millipore was followed. Briefly, cells were incubated in RPMI1640
media supplemented with 1%PSG only for 24 hours. 36105 cells
were plated into each insert in RPMI1640 with 0.5% BSA and
treated with DHT 1 nM, Dox 4.5 ng/mL, Dox 20 ng/mL and
vehicle only as control. Individual treatments were completed in
duplicate. 500 mls of RPMI1640 supplemented with 10% FBS was
added to bottom chambers and cells were incubated for 48 hours.
Cells/media from the top side of each insert were removed and
inserts were incubated in 225 mls of Cell Detachment Solution for
30 minutes at 37uC. 75 mL of Lysis Buffer/CyQUANTH GR Dye
Solution was added to each well containing Cell Detachment
Solution and inserts were incubated in it for 15 minutes at room
temperature. 200 mL of each mixture was added to one well of a
96-well plate and fluorescence absorbance was measured by a
fluorescence plate reader with a 480/520 nm filter set.
Microarray
LN/TC-AR cells were treated with DHT 1 nM, Dox 4.5 ng/
mL, Dox 20 ng/mL and vehicle only as control in 10%CDT
media for 24 hours after 3 days in 10%CDT media. Total RNA
was extracted by using QIAshredder and RNeasy Mini Kit and
following the protocols from QIAGEN. Two independent
experiments were performed and RNA samples were submitted
to the UC Davis Cancer Center Gene Expression Resource
facility. Microarray analysis was done using Affymetrix Human
Genome U133 Plus 2.0 arrays (Affymetrix, South San Francisco,
CA). Analysis of the expression data from the Dox 4.5 ng/mL-
treated cells, Dox 20 ng/mL-treated cells and DHT-treated cells
versus the vehicle-treated cells was conducted using DNA-Chip
Analyzer software. Filter criteria are p#0.05, signal log ratio $0.6
(1.5fold) and present (P) for detection. Gene Ontology (GO)
analysis was performed by DAVID Functional Annotation tools
(http://david.abcc.ncifcrf.gov/home.jsp) and Gene Set Analysis
Toolkit [16].
qRT-PCR
RNA was isolated as described in Microarray section. Comple-
mentary DNA synthesis was done using SuperScriptH III Reverse
Transcriptase Kit (Invitrogen) according to the manufacturer’s
protocol. 2 ng cDNA was amplified by iQ5 iCycler thermal cycler
(Bio-Rad) and monitored by SYBRGreen (Invitrogen) for real time
PCR. Threshold cycle values were normalized against actin or
GAPDH. Individual samples were performed in triplicate and
converted to relative gene expression using QGene96 software
(http://www.gene-quantification.de/download.html#qgene). Se-
quences for each primer set are in Table S3.
Chomatin immunoprecipitation (ChIP)
ChIP assays (26107cells/assay) were performed following the
University of California Davis Genome Center ChIP protocol
(http://genomics.ucdavis.edu/farnham). The primary antibodies
used in the assays were a-FLAG M2 antibody (Sigma) and a-RNA
polymerase II 8WG16 monoclonal antibody (Covance). KLK3
promoter primer sequences are: 59-TCTGCCTTTGTCCCCTA-
GAT-39 (forward) and 59-AACCTTCATTCCCCAGGACT-39
(reverse) [17].
ChIP to chip analysis
ChIP assays (26107cells/assay) were performed following the
University of California Davis Genome Center ChIP protocol
(http://genomics.ucdavis.edu/farnham). The primary antibody
used in the assays was a-FLAG M2 antibody (Sigma-Aldrich).
LN/TC-AR cells were treated with 10 ng/mL doxycycline for
24 hours after three days in RPMI supplemented with 10%
charcoal dextran treated (CDT) fetal bovine serum and 1% PSG.
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Two independent ChIP experiments were performed and a-
FLAG M2 antibody was used for detecting occupancy of FLAG-
tagged TC-AR on chromatins. One total input, one IgG control
and two LN/TC-AR ChIP samples were collected and sent to the
UCD Cancer Center Gene Expression Resource Facility for
hybridization [18]. Data analysis was performed with CisGenome
software [19]. TC-AR binding regions were identified by
comparison to total input control as well as IgG control using
the TileMap peak detection tool [20]. Genomic locations of
binding peaks were visualized in the CisGenome browser.
Results
Titration of doxycycline induction yields a physiologically
relevant level of TC-AR expression in the newly
established LN/TC-AR cell line
LN/TC-AR is a newly developed cell line derived from the
parental LNCaP line in which a truncated form of the androgen
receptor (TC-AR) is expressed following doxycycline induction
(Figure 1B). Titration of doxycycline levels showed that TC-AR
expression was maximal when cells were cultured in complete
media supplemented with 10 ng/mL doxycycline (data not
shown). A second, more focused titration showed that a
physiologically relevant level of TC-AR expression (as defined
here by similarity to AR expression in the CWR22Rv1 cell line)
was achieved when cells were cultured in complete media
supplemented with 4.5 ng/mL doxycycline (Figure 1C). In
subsequent studies involving this cell line, induction of TC-AR
with 4.5 ng/mL doxycycline (Low Dox) is used to approximate
physiological levels of expression while increased doxycycline
concentrations (High Dox) are used to induce ‘‘overexpression’’ of
TC-AR.
Induction of exogenous AR causes a concomitant
decrease in endogenous AR protein and mRNA levels
Immediately apparent in the doxycycline titrations is the inverse
relationship between the induced exogenous TC-AR and endog-
enous FL-AR protein levels (Figure 1C). In order to investigate
whether this effect is limited to post-translational regulation or is
also observed at the transcriptional level, real time quantitative
reverse transcriptase PCR (qRT-PCR) analysis of endogenous FL-
AR in LN/TC-AR was performed. Following induction of TC-
AR with Low Dox, a progressive decrease was observed in
endogenous FL-AR mRNA at 3, 6, 9 & 12-hour time points after
which FL-AR mRNA levels appeared to stabilize at approximately
40% that of normal uninduced cells (Figure 1D). A similar pattern
was observed in cells induced with High Dox with endogenous FL-
AR mRNA levels decreased to 12% of control at the 24-hour time
point. Under the latter conditions FL-AR protein was undetect-
able by western blot analysis. While we can never exclude the
expression of FL-AR in these cells, its contribution should be
minimal.
FL-AR and TC-AR do not form a heterodimer in LN/TC-AR
As heterodimerization of a similarly truncated AR form
(ARv567es) and FL-AR has been reported [11], we attempted a
co-immunoprecipitation of TC-AR and FL-AR using induced
LN/TC-AR lysates (Figure 1E). To avoid the significant decrease
in FL-AR expression following induction with greater than 4 ng/
mL doxycycline (Figure 1C), this assay was completed with lysates
harvested from LN/TC-AR induced with 4 ng/mL doxycyline.
As expected, IP with a-FLAG M2 agarose beads precipitated the
FLAG-tagged TC-AR; however, co-precipitation of FL-AR was
not observed indicating that TC-AR does not form a heterodimer
with FL-AR in the LN/TC-AR cell line.
TC-AR is transciptionally active in the absence of DHT
In order to examine the ability of TC-AR to facilitate
transcription at an AR-regulated promoter, a luciferase assay
using the full-length PSA promoter was completed. Immediately
following co-transfection of pPSA6.0-luc and pH 48-ren reporter
plasmids, expression of TC-AR in LN/TC-AR was induced with
various concentrations of doxycycline. Transfected, but unin-
duced, LN/TC-AR cells treated with either 1.0 nM DHT or
vehicle (EtOH) serve as positive and negative controls, respective-
ly. Luciferase production (dependent upon activity of the upstream
PSA promoter) was found to be significantly increased in all
doxycycline-treated samples relative to untreated control
(Figure 2A). Furthermore, transcriptional activity measured for
each of the TC-AR expressing samples was three to seven fold
higher than that found in the uninduced DHT-treated control in
which luciferase production is controlled solely by DHT-bound
endogenous AR.
TC-AR localizes to the nucleus and is able to bind
androgen response elements (AREs) in chromatin in the
absence of DHT
In order to observe localization of TC-AR, immunostaining of
LN/TC-AR was completed. Contrary to endogenous AR which
has been shown to remain in the cytoplasm in the absence of
DHT, TC-AR localized predominantly to the nucleus following
induction with Low Dox (Figure 2B). Chromatin immunoprecip-
itation (ChIP) assay was performed to assess binding of TC-AR to
the AR-regulated KLK3 promoter (Figure 2C). Occupancy of the
KLK3 promoter by TC-AR following doxycycline induction of
LN/TC-AR cells was observed. Unlike wild-type AR, DHT was
not required for the binding of TC-AR to the KLK3 promoter [17].
RNA polymerase II was also found at the KLK3 promoter thus
demonstrating the transcriptional activation of an endogenous
androgen regulated gene by TC-AR in the absence of DHT.
Induction of TC-AR in the LN/TC-AR is sufficient for ADI
growth
In order to test whether expression of TC-AR could result in
androgen independent growth of the normally androgen depen-
dent LNCaP cell line, a cell count assay was performed
(Figure 2D). Uninduced LN/TC-AR cells cultured in 10%
charcoal dextran treated FBS (CDT-FBS) in the presence or
absence of 1.0 nM DHT serve as ‘‘normal’’ and ‘‘androgen
depleted’’ controls, respectively. As expected, culture in androgen
depleted medium caused an inhibition of cell growth while those
cells grown in normal conditions proliferated as expected.
Following induction of TC-AR with Low Dox, LN/TC-AR cells
grew in the absence of DHT. Induction with High Dox exhibited a
similar phenotype of androgen independent growth, albeit to a
lesser degree.
Cell shape and motility of LN/TC-AR is influenced by the
level of TC-AR expression
In addition to the biochemical properties of TC-AR described
above and growth characteristics following its induction in LN/
TC-AR, cell shape changes were also observed. LN/TC-AR cells
were cultured in media containing 10% CDT-FBS and supple-
mented with 1 nM DHT, Low Dox, High Dox or vehicle (EtOH)
only. Representative images were taken of each culture 48-hours
post-treatment (Figure 3A). As has been previously described for
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the parental LNCaP cell line [21], culture in androgen depleted
medium (10% CDT-FBS) stimulates the extension of what has
been described as ‘‘neuritic processes’’ in uninduced LN/TC-AR.
Culture of LN/TC-AR in the presence of Low Dox decreases this
‘‘branching’’ morphology and, in fact, the cell shape is quite
similar to uninduced LN/TC-AR grown in the presence of 1 nM
DHT. However, induction of TC-AR with High Dox causes a
significant change in cell shape in that the characteristic slender
cell body normally associated with LNCaP is no longer present.
This effect was also observed in cells induced with Low Dox;
however, not until approximately six days post-induction (Figure
S1). Also observed in LN/TC-AR cells induced with High Dox
was a two-fold increase in cell motility relative to uninduced LN/
TC-AR (Figure 3B). This increased motility was not observed in
LN/TC-AR grown in the presence of 1 nM DHT or Low Dox for
the same period of time.
Identification and validation of TC-AR target genes
Genome-wide microarray expression profiling with human
genome Affymetrix Human Genome U133 Plus 2.0 arrays was
completed to compare gene regulation by induced TC-AR and
DHT-bound endogenous AR. Analysis showed that there were
197 genes with differential expression following treatment with
1.0 nM DHT, 339 genes following treatment with Low Dox and
379 genes following treatment with High Dox (filter criteria:
p#0.05, signal log ratio $0.6 and present (P) for detection). There
were 45 genes commonly up-regulated and 35 genes commonly
downregulated by each of the three treatments (Figure 4A). Some
well-known AR-responsive genes, such as KLK2, KLK3, KLK4,
FKBP5 and TMPRSS2, were among the commonly up-regulated
genes, which showed that TC-AR shared some common biological
influence with endogenous AR (Table S1). However, greater than
half of upregulated genes identified in the Low Dox group
overlapped with upregulated genes in the High Dox group but not
the DHT treatment group.
Based on the microarray data, we acquired a list of genes which
were upregulated by both Low Dox and High Dox treatment
groups (Table S2). To confirm the microarray results, qRT-PCR
was performed on several of these genes. Each of the genes tested
showed higher expression in doxycycline treatment groups relative
to untreated controls (Figure 4B). Microarray analysis of the
expression levels of the TC-AR selectively upregulated PDZD2,
SHROOM3, SOCS2, ACVR1B, STYK1, RHOB, FGD4, SSX2IP,
CDC25A, and CHPT1 genes showed no significant increase
following DHT treatment. qRT-PCR analysis of these genes
showed that each was upregulated in the doxycycline treatment
groups relative to the DHT treatment group, thus confirming the
results obtained via microarray. Among these genes, RHOB seems
to have the most robust upregulation by TC-AR, but not by DHT-
bound FL-AR. This, together with its role in cell migration, was
the basis for further examination.
Figure 2. TC-AR is transcriptionally active in the absence of
DHT and confers ADI growth in vitro. A Luciferase assay showing
DHT-independent transcription of a transiently transfected AR regulat-
ed promoter following induction of TC-AR in LN/TC-AR. LN/ TC-AR cells
were co-transfected with pPSA6.0-luc and pH 48-ren in hormone
depleted media and treated with either low concentrations of
doxycycline, DHT 1 nM or vehicle as control for 24 hours. Fold
induction is relative to untreated control. B Immunostaining of LN/
TC-AR shows androgen independent nuclear localization of TC-AR
(right). Cells were counterstained with DAPI to identify nuclei (left) and
images were acquired with an Olympus fluorescent microscope using
206 magnification. C Chromatin Immunoprecipitation (ChIP) showed
the recruitment of AR and RNA polymerase II to the KLK3 promoter. LN/
TC-AR cells were pre-cultured in androgen depleted medium for
72 hours then treated with Low Dox for 24 hours. Anti-FLAG M2 (for
FLAG-tagged TC-AR) and a-RNAP2 antibody were used in separate
aliquots to immunoprecipitate cross-linked protein and DNA. D Cell
count assay showing the growth of LN/TC-AR in hormone depleted
media following treatment with 1 nM DHT, Low Dox, High Dox or
vehicle as control.
doi:10.1371/journal.pone.0049887.g002
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Knockdown of RHOB affects cell morphology and cell
migration of LN/TC-AR cells under doxycycline
treatments
RHOB, a small GTPase, is a member of the Ras-homologous
(Rho) gene family, which plays a role in cell motility, apoptosis
response and actin organization [22,23]. The aforementioned
microarray data showed the overexpression of RHOB is selectively
induced by TC-AR. Western blot analysis confirmed the
overexpression of RHOB protein in LN/TC-AR treated with
Low and High Dox, but not in DHT treated cells without Dox
induction (Figure 5A). Furthermore, ChIP to chip analysis
revealed that under High Dox conditions, TC-AR is recruited to
3880 bp and 47521 bp downstream of transcription end site (TES)
of RHOB (Figure 5B). Given the significant alterations of the cell
morphology of LN/TC-AR upon doxycycline induction, we asked
whether RHOB contributes to these changes.
To this end, shRNA was used to knock down RHOB expression
in the LN/TC-AR cell line. Two new cell lines were established:
LN/TC-AR/shR-RHOB in which shRNA targeting endogenous
RHOB is constitutively expressed (TC-AR expression remains
doxycycline dependent) and LN/TC-AR/shR-empty in which the
shRNA sequence targeting RHOB has been removed. Western
blot analysis of these lines revealed efficient knockdown of RHOB
expression even following indirect induction with doxycycline via
TC-AR-mediated upregulation (Figure 5C).
Images of LN/TC-AR/shR-RHOB cells were taken following
treatment with 1 nM DHT, Low Dox or High Dox and culture in
androgen depleted media for 48 hours. The shape of doxycycline-
induced LN/TC-AR/shR-RHOB cells remained the same as
DHT treated or control cells (Figure 5D). We then tested the effect
of lower expression of RHOB on the migration of doxycycline-
induced LN/TC-AR cells by performing a migration assay. The
result showed that knockdown of RHOB negates the TC-AR
overexpression mediated increase in migration of the LN/TC-AR
cell line (Figure 5E). In order to test if knockdown of RHOB affects
ADI growth of LN/TC-AR cells, an MTT assay was performed.
LN/TC-AR/shR-RHOB cells were treated with 1 nM DHT,
Low Dox, High Dox or vehicle as control and an MTT assay was
completed on indicated days. Knockdown of RHOB did not affect
the growth of DHT-treated cells, control cells or Low Dox-treated
cells (Figure 5F). Thus, RHOB is likely to play a significant role in
the morphological changes and migratory properties in LN/TC-
AR cells, but not significantly involved in the proliferation of the
cells.
Figure 3. Cell shape and motility change of LN/TC-AR under different dox treatments. A LN/TC-AR cells were grown in the presence of
hormone depleted media and treated with various concentrations of doxycycline or 1 nM DHT. CWR22Rv1 cells were grown in RPMI supplemented
with 10% FBS. At 48-hours post-treatment representative images of each sample group were acquired. B LN/TC-AR cells were pre-cultured in serum
free media (SFM) for 24 hours then seeded to migration chambers with various treatments in the presence of SFM for an additional 48 hours after
which time fluorescence was detected. Fold induction is relative to untreated control.
doi:10.1371/journal.pone.0049887.g003
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Discussion
It has been previously reported that simple overexpression of
AR is sufficient to circumvent the normal androgen dependency of
the LNCaP cell line [24] while severe overexpression of AR has
deleterious effects [25]. Currently absent from the literature is a
stable cell line in which physiologically relevant expression of AR
forms are achieved. We have reported here the development of
LN/TC-AR, a novel cell line in which TC-AR is inducible and
titratable by doxycycline. This single cell line can closely
recapitulate the balance between full-length and truncated forms
of AR (Low Dox), mimic parental LNCaP (uninduced) or serve as
a TC-AR ‘‘overexpression’’ line (High Dox) which has been useful
to expedite/amplify subtle morphological and phenotypical
characteristics. As a result, confounding variables present in
studies which would otherwise utilize several cell lines are greatly
reduced.
The truncated form of AR expressed in LN/TC-AR amounts to
a ‘‘hybrid’’ receptor designed to be representative of naturally
occurring C-terminally truncated AR forms. The stop codon is
placed at Q641, the site of a non-sense mutation identified in a
metastatic tumor taken from a patient whose disease had
circumvented androgen deprivation therapy [26]. TC-AR also
bears the exon 3 duplication identified in CWR22Rv1, and, like
ARv567es (but not AR3/AR-V7), TC-AR retains the hinge domain
and an intact nuclear localization signal. In order to ensure that
these features did not confer unique activity relative to other
possible forms of truncated AR, we tested a total of six similar
forms of AR which varied in location of stop codon (R629, Q641
and V662) and the presence or absence of the exon 3 duplication
and found DHT independent transactivation of each to be highly
similar. We have also generated LN/TC-AR* which expresses an
AR form with the same translational termination as TC-AR, but
only a single exon 3. This receptor corresponds precisely to the
aforementioned AR(Q641Stop) CRPC mutation [26]. Consistent
with our previous report [2] and those of others [6], the addition of
an extra exon3 does not seem to significantly affect the biological
and biochemical properties of AR as transactivation, growth and
cell shape studies for this cell line were consistent with results
obtained using LN/TC-AR (Figure S2).
In establishing optimal expression of TC-AR, we observed the
downregulation of endogenous AR following TC-AR induction. It
has been previously reported that AR mRNA levels can be
downregulated or upregulated by androgen depending on cell and
tissue types [27] In order to limit the confounding effects of
androgen withdrawal, the data presented here was obtained from
assays completed in the presence of complete medium. It is worth
noting that a similar pattern of repression was also observed in
cells cultured in the absence of androgen. In addition to the
expected decrease in AR protein levels following androgen
withdrawal which is only exacerbated by induction of TC-AR,
the abundance of AR mRNA decreased to approximately 50–75%
that of uninduced controls (Figure S3). In LNCaP cells, studies
indicate that androgen-mediated downregulation of AR mRNA
levels is due to the decreased transcription of the AR gene [28,29]
as opposed to increased rate of mRNA turnover. There is no
androgen response element (ARE) in the promoter of AR;
however one study identified four AREs within the coding region
of AR, but these AREs were reported to be involved exclusively in
upregulation of AR mRNA [30]. An AR suppressor element
(mARS) was identified in the mouse 59UTR [31] with a similar
element later identified in the human 59UTR which was reported
to be responsible for the decrease of AR promoter activity in
androgen-dependent LNCaP cells [32].
Figure 4. Comparison of gene expression in LN/TC-AR follow-
ing induction of TC-AR or treatment with DHT. A Venn diagram
of microarray analyses of LN/TC-AR cells treated with 1 nM DHT or
different concentrations of doxycycline for 24 hours post serum
starvation. Numbers indicate genes that were commonly or uniquely
upregulated (q) or downregulated (Q) following the various
treatments. B LN/TC-AR cells were treated with Low Dox, High Dox,
1 nM DHT, or vehicle in hormone depleted media for 24 hours.
Quantitative RT-PCR was performed for the selected genes. Fold
induction is relative to values obtained in untreated control using
identical gene specific primers.
doi:10.1371/journal.pone.0049887.g004
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Figure 5. Knockdown of RHOB affects cell shape and cell migration following overexpression of TC-AR in LN/TC-AR/shR-RHOB. A
LN/TC-AR cells were pre-cultured in hormone-depleted media for 48 hours then treated with Low Dox, High Dox, 1 nM DHT or vehicle for 24 hours.
Whole cell lysates were harvested and subjected to western blot analysis. Membranes were probed with a-RHOB or a-actin. B Graphic representation
of TC-AR binding sites 100 kb within the region of adjacent to RHOB gene. Arrows above show TC-AR binding sites (+3.8 kb and +47.5 kb
downstream of TES). C Androgen-deprived LN/TC-AR/shR-empty and LN/TC-AR/shR-RHOB cells were treated with 1 nM DHT, Low Dox, High Dox or
vehicle only. Whole cell lysates were harvested 48-hours post-treatment and subjected to western blot analysis. Membranes were probe with either
a-RHOB (top) or a-actin (bottom). D Androgen-deprived LN/TC-AR/shR-RHOB cells were treated with 1 nM DHT, Low Dox, High Dox or vehicle.
Images were acquired 48-hours post-treatment. E LN/TC-AR/shR-RHOB cells were pre-cultured in serum free media (SFM) for 24 hours then seeded to
migration chambers with various treatments in the presence of SFM for an additional 48 hours after which time fluorescence was detected. Fold
induction is relative to untreated control. Prior results for LN/TC-AR (from Figure 3B) are included for comparison. F MTT assay of LN/TC-AR/shR-RHOB
in hormone depleted media following treatment with 1 nM DHT, Low Dox, High Dox or vehicle as control showing that DHT independent growth
previously shown for LN/TC-AR (Figure 2D) is not inhibited by knockdown of RHOB. Bright field images were acquired with an Olympus microscope
using 206magnification.
doi:10.1371/journal.pone.0049887.g005
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Most recently, AR auto-repression was found to be due to the
assembly of a FL-AR repressive complex containing lysine-specific
demethylase 1 at the intron 2 enhancer [33]. We show here that
AR autorepression is not limited to liganded FL-AR, but is effected
by TC-AR as well. Unlike the similar ARv567es, co-immunopre-
cipitation assays revealed no detectable heterodimerization
between FL-AR and TC-AR either in a transient transfection
assay [2] or in LN/TC-AR (Figure 1E). While this result excludes
repression by FL-AR/TC-AR heterodimers, a similar mode of
repression by TC-AR homodimers is plausible and warrants
further investigation within the context of LN/TC-AR and other
truncated AR models.
At a minimalistic level, three criteria must be met for a
truncated form of AR to be considered a potential surrogate for
DHT-bound FL-AR in the absence of DHT: a) it must retain the
ability to localize to the cell nucleus, b) facilitate transcription of
AR target genes and, c) ‘‘rescue’’ the effect of growth inhibition.
Immunostaining of LN/TC-AR following induction with Low
Dox reveals that TC-AR predominantly localizes to the cell
nucleus in the absence of DHT. Although a commonly used
reporter assay (transient transfection of pPSA-luciferase) served as
a first screen of LN/TC-AR, that assay is not representative of
gene activation in chromatin. Via ChIP analysis of LN/TC-AR
we have shown KLK3 promoter occupancy by TC-AR and
RNAP2 in the absence of DHT. KLK3 was also found by
microarray analysis to be upregulated by TC-AR. Together, these
results demonstrate that TC-AR is able to facilitate transcription at
an endogenous AR-regulated promoter in the absence of DHT.
Lastly, we have shown that TC-AR expression is sufficient to
confer ADI growth to the normally AD LNCaP cell line and that
this effect is tethered tightly to the physiologically relevant
expression of TC-AR. LN/TC-AR induced with 3 ng/mL
doxycycline fail to grow in conditions of androgen deprivation
while cells induced with 5–10 ng/mL doxycycline show ADI
proliferation inversely proportional to doxycycline concentration.
This is consistent with recent reports in which the growth-
promoting effects of some AR splice variants were mediated
through FL-AR [15] given the reduction in FL-AR following
overexpression of TC-AR. In a subsequent assay, however, it was
determined that the AR inhibitor MDV3100 does not repress ADI
growth of LN/TC-AR when both AR forms are expressed (not
shown).
Although these basic biochemical properties of TC-AR closely
approximate DHT-bound endogenous AR in LNCaP, microarray
analysis of regulated genes has shown that, while there is
significant overlap between the two as would be expected, there
also exist differences in that pool of genes. One explanation for this
difference could be the differential assembly of cofactors. Common
to both TC-AR and endogenous full-length AR is the N-terminal
domain (NTD) which serves as the primary binding region for
cofactors such as SRC-1 and GRIP1 [34] and contains activation
function-1a (AF-1a) and AF-1b [35] which are the major AF
regions of AR. Despite retention of these domains, it is unclear if
and how the loss of the LBD affects cofactor recruitment and/or
binding in TC-AR.
Comparisons of existing transcriptome studies can be difficult
given variances in model systems, growth conditions, sample
preparation and the wide selection of platforms for such analyses.
This is evident in a comparison of the data acquired here with
those of two prior studies in which the transcriptome of a similarly
truncated AR form, denoted either AR3 [8] or AR-V7 [36] was
interrogated. Comparison of our microarray data and data
generated in those studies shows very little commonality and
qRT-PCR analysis confirmed microarray data showing that three
genes of focus in those studies (AKT1, CDC20 & UBE2C) are not
upregulated following induction of TC-AR in the LN/TC-AR
model (Figure S4). However, the data acquired here is consistent
with a third study in which the transcriptome of ARv567es was
assayed [11]. Among the 26 top-upregulated genes identified in
that study, 15 were confirmed here with three upregulated by FL-
AR only (BRP44, DHCR24 & HERC3), seven upregulated by TC-
AR only (IDI, ORM1, SSR3, SC4MOL, SEC24D, SGK1 & STEAP4)
and five common to the transcriptomes of both FL-AR and TC-
AR (ELL2, MBOAT2, SLC45A3, STK39 & TMPRSS2). Also
common to both TC-AR and ARv567es is the hinge region and
intact nuclear localization signal. This region is potentially a
source of variation in these studies as it is not present in AR3/AR7
which instead terminates with amino acids encoded by a cryptic
exon.
Early in our characterization of LN/TC-AR, we found that cell
shape changed rapidly following severe overexpression of TC-AR
and at a much slower rate and to a slightly lesser degree following
induction of physiologically relevant levels of TC-AR. As
deregulated cell adhesion of tumor cells, often first observed as a
change in cell shape, can lead to cell detachment and promote cell
invasion [37], we hypothesized that migration of LN/TC-AR may
be affected by modulation of TC-AR expression. We found that
LN/TC-AR displayed a two fold increase in migration following
overexpression of TC-AR and that this result correlated with the
striking change to cell shape. We hypothesized that FGD4, RHOB
or SSX2IP, all determined to be upregulated in microarray and
western blot studies and known to be involved in cell adhesion, cell
shape or cell motility, may be involved in this phenotypic change.
We generated LN/TC-AR/shR-FGD4, LN/TC-AR/shR-
RHOB and LN/TC-AR/shR-SSX2IP and, although all lines
showed significant knockdown of either FGD4, RHOB or
SSX2IP, only LN/TC-AR/shR-RHOB negated the cell shape
changes caused by overexpression of TC-AR (data not shown).
Consistent with the observation of cell shape, a repeat of the
migration assay, this time using LN/TC-AR/shR-RHOB in place
of LN/TC-AR, showed that overexpression of TC-AR failed to
cause an increase in migration.
Rho GTPase, RHOA, RHOB and RHOC are known for
regulation of the cytoskeleton, cell motility and cell cycle [22,38].
Based on our microarray data, the expression of RHOA and
RHOC were not significantly changed by the induction of TC-AR
(data not shown). However, we found that the expression of
RHOB mRNA and protein levels were significantly elevated in
doxycycline-treated LN/TC-AR cells. While the function of
RHOB in disease progression is complex and context dependent
[38–42], we have shown here that RNAi-mediated silencing of
RHOB inhibited the change of cell shape as well as cell migration
of LNCaP expressing TC-AR. Similarly, a recently published
report has shown that overexpression of RHOB in the ADI CaP
line DU145 enhances cell migration [43]. Lastly, RHOB has been
shown to be upregulated and negatively affect cell proliferation of
some types of cancer cells [23]. MTT analysis of the growth of
LN/TC-AR/shR-RHOB supports this role of RHOB as the high
degree of cell death following significant overexpression of TC-AR
in LN/TC-AR is not observed in LN/TC-AR/shR-RHOB.
To summarize, we present here a new cell line to study the
effect of truncated AR on the progression of prostate cancer to an
androgen depletion independent disease. As part of our initial
characterization of one such representative form of truncated AR,
we have shown that, similar to DHT-bound endogenous full-
length AR, the ligand independent truncated AR retains the
ability to translocate to the cell nucleus where it is able to bind
AREs within chromatin and facilitate transcription of a host of
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androgen regulated genes. Beyond this similarity, we have
identified differences in the targets of transcriptional upregulation
with one such difference being the upregulation of RHOB, a gene
whose expression is not influenced by DHT-bound full-length AR.
As validation of the usefulness of this model cell line, we have
shown the upregulation of RHOB to be involved in the increased
motility and morphological changes evident in androgen depletion
independent growth conferred by the truncated AR.
Supporting Information
Figure S1 LN/TC-AR cells were grown in the presence of
hormone depleted media and treated with 4.5 ng/mL of
doxycycline (low dox) or left untreated as control for 6 days.
Media and doxycycline were refreshed every 3 days. Bright field
images were acquired with an Olympus microscope using 206
magnification.
(TIF)
Figure S2 A Western blot showing TC-AR* levels of LN/TC-
AR* lines. Doxycycline concentrations are shown above the
membrane image. Membrane were probed with a-AR (PG-21)
(primary) followed by a-mouse (secondary). Simultaneous with a-
AR (PG-21), each membrane was also probed with a-actin
(primary) as a control for loading. B Morphology of LN/TC-AR*
cell line following induction of TC-AR*. LN/TC-AR* cells were
grown in the presence of hormone depleted media and treated
with various concentrations of doxycycline (listed immediately
above images). At 48-hours post-treatment representative images
of each sample group were acquired. C Androgen independent
growth of the LN/TC-AR* cell line. Cell count assay showing the
growth of LN/TC-AR*. Cells were cultured in androgen-depleted
medium that was supplemented with either 1 nM DHT, low dox,
high dox or vehicle only. At the designated time points, total cells
per well were determined via CountessH Automated Cell Counter.
D Luciferase assay showing androgen-independent activation of
TC-AR* Luciferase assay showing that TC-AR*-mediated
transactivation is not dependent upon androgen within the context
of the LN/TC-AR* cell line. LN/TC-AR* cells were co-
transfected with pPSA6.0-luc and pH 48-ren in hormone depleted
media and treated with low concentrations of doxycycline (listed
below the graph) and either 1 nM DHT or vehicle as control for
24 hours. Fold induction is reported relative to uninduced LN/
TC-AR* cells grown in the absence of DHT.
(TIF)
Figure S3 AR mRNA in LN/TC-AR cultured in androgen
depleted medium decreases following induction of TC-AR. Graph
shows data obtained from two separate microarray probe clusters
targeting the LBD and 39UTR of AR. Neither region is present in
TC-AR thus ensuring analysis of only endogenous AR mRNA.
Cluster 211110_s_at contains a mix of 11 probes spanning
nucleotides 3386–3950 (Exon 5 to 39UTR) and cluster 211621_at
contains a mix of 11 probes spanning nucleotides 4010–4251
(39UTR). All samples for microarray analysis were prepared as
described in the main text. Nucleotide positions are based on
NCBI Reference Sequence NM_000044.3.
(TIF)
Figure S4 Quantitative Real Time PCR Analysis of AKT1,
CDC20 & UBE2C. qRT-PCR was performed as described in
Materials and Methods using primers shown in Table S3. Results
show no significant upregulation of these three genes following
induction of TC-AR in the LN/TC-AR cell line.
(TIF)
Table S1 Genes up-regulated by DHT, Low Dox and High Dox
treatments
(XLSX)
Table S2 Genes up-regulated by Low Dox and High Dox
treatments
(XLSX)
Table S3 Sequences of primers for q-RT-PCR
(XLSX)
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